ExeGi Pharma LLC, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today that it has launched Visbiome ® Vet, a new high potency probiotic for use in companion dogs to help support normal inflammatory responses in the gastrointestinal tract (GI tract) and to help normalize gut health.
The formulation in Visbiome Vet contains an eight-strain proprietary probiotic blend that has recently been studied in several canine GI disorders, with two clinical trials published in the last 12 months. Visbiome Vet is the identical formulation to Visbiome®, a human medical food that has been the subject of over 60 clinical trials.
“Serious gastrointestinal conditions in dogs is often linked to alterations in the GI bacterial community, commonly known as the gut microbiome,” said Dr. Jan Suchodolski, PhD, DACVM at Texas A&M University. “This formulation has been shown in a variety of trials to help normalize gut health.”
Visbiome Vet contains 112.5 billion live bacteria per dosage, a potency that far exceeds other conventional veterinary probiotics. The product, only available to veterinarians and veterinary pharmacies, is packaged conveniently for veterinary applications. Visbiome Vet is shipped and stored only under refrigerated conditions to ensure maximum product potency.
“Over the last year we have been overwhelmed by pet owners telling us about the tremendous results they were experiencing using our human Visbiome product with their pets,” said Marc Tewey, CEO of ExeGi Pharma. “We are pleased to finally bring this high potency probiotic formulation to the veterinary community with Visbiome Vet.”